title: Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
abstract: Bendamustine is a alkylating agent with a purine-like benzamidazole ring currently approved in Europe for indolent non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and multiple myeloma. Our aim was to analyze retrospectively the efficacy and toxicity of bendamustine in NHL and CLL in Spain in the bendamustine Compassionate Use Program. Patients with relapsed/refractory NHL or CLL were eligible. Any regimen containing bendamustine was eligible. 109 patients were included from 22 institutions. Forty-nine patients had indolent NHL, 18 aggressive NHL and 42 CLL, being 44 patients (40%) refractory to previous treatment. 63% of patients had adverse events grade 3-4, mainly hematological. Overall response rate (ORR) was 66%, complete responses 30%. ORR observed in refractory patients was 45%. The median progression-free survival (PFS) was 13 months. Outcome was influenced by histology, number of previous treatments, resistance to previous chemotherapy and type of response achieved with bendamustine. Alone or in combination, bendamustine shows a meaningful clinical antitumor activity in patients with relapsed or refractory NHL or CLL, with an acceptable toxicity profile.
authors.affiliation: Department of Hematology, Hospital del Mar, Passeig Maritim, Barcelona, Spain. 97894@parcdesalutmar.cat
authors.forename: Blanca
authors.initials: B
authors.lastname: Sanchez-Gonzalez
authors.forename: F Javier
authors.initials: FJ
authors.lastname: Peñalver
authors.forename: Angeles
authors.initials: A
authors.lastname: Medina
authors.forename: Helga
authors.initials: H
authors.lastname: Guillén
authors.forename: Marta
authors.initials: M
authors.lastname: Calleja
authors.forename: Mercedes
authors.initials: M
authors.lastname: Gironella
authors.forename: Reyes
authors.initials: R
authors.lastname: Arranz
authors.forename: Elena
authors.initials: E
authors.lastname: Sebastian
authors.forename: Raquel
authors.initials: R
authors.lastname: de Oña
authors.forename: Araceli
authors.initials: A
authors.lastname: Cánovas
authors.forename: Ignacio
authors.initials: I
authors.lastname: de la Fuente
authors.forename: Carlos
authors.initials: C
authors.lastname: Grande
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Sancho
authors.forename: Ricardo
authors.initials: R
authors.lastname: Perez
authors.forename: Eva
authors.initials: E
authors.lastname: Domingo
authors.forename: José Luis
authors.initials: JL
authors.lastname: Lopez-Lorenzo
authors.forename: Elena
authors.initials: E
authors.lastname: Prieto
authors.forename: Carlos
authors.initials: C
authors.lastname: Panizo
authors.forename: Ana
authors.initials: A
authors.lastname: Gorosquieta
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Perez
authors.forename: Jose Manuel
authors.initials: JM
authors.lastname: Cervera
authors.forename: Miguel
authors.initials: M
authors.lastname: Marin
authors.forename: Carmen
authors.initials: C
authors.lastname: Mencha
authors.forename: Elena
authors.initials: E
authors.lastname: Ramila
authors.forename: Antonio
authors.initials: A
authors.lastname: Salar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D057176:Compassionate Use Trials; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013030:Spain; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride